Check our Patient Information in PDF
Advanced Cancer Diagnostics logo
Chronix Biomedical logo
Patient
information
diagnostics tests
for cancer
bauble-blue
28 Bolton Street
London WIJ 8BP
bauble-blue
+44 207 629 9933
bauble-blue
advancedcancerdiagnostics.com
enquiries@advancedcancerdiagnostics.com
#TheTurningPointInCancerFight
“This is the most accurate test
on the market”
Howard Umovliz,
CEO Chronix Biomedical
“Oncologists believe this type of blood test will become an invaluable piece of the cancer treatment puzzle”
The times, 30th August 2016
“Imagine being able to tell a patient after only one cycle that the chemotherapy is not working, and that they wonʼt have to go through five more cycles of toxic drugs that could be worse for them.”
Clinica, 18th April 2016
“Used for diagnosis, prognosis and most importantly prediction, providing a real time measure from a simple blood test of how a patient is responding.“
Justin Stebbing, Professor of cancer medicine and medical oncology at Imperial College London
CNI Technology

Chronix Biomedical has now made available a laboratory developed test for the detection of risk factors highly associated with cancer. We know today that cancer – in a large number of cases – is characterized by strong changes in the DNA. Cancer cell DNA differs from all other normal cells of the body. This difference can be detected with modern laboratory procedures.

 

Through the simple process of drawing blood, we can now offer a test that can, with a high degree of accuracy, detect macromolecular mutations of DNA fragments in blood plasma, which are closely associated with cancer. This blood test is a new measure that can help in the early detection of cancer. However, the test is not intended to replace the regular preventive examinations, which you should continue to use.

Our assay will calculate a measured value based on the 16 ml blood sample you provide. If the measured value is within the limits of what we find in healthy people, there is no evidence in the sample of a cancer at that point in time. If the first result shows a higher value, we will recommend further diagnostic measures to your doctor.

 

With this test, it is possible to detect some cancers before they are noticed by symptoms. Once confirmed, a therapy can then be initiated at an earlier stage than before. Some cancers may not be detectable by our blood test, so a negative result does not exclude a cancer with certainty. It is also possible that no cancer can be found despite the increased measured value.

Chronix Biomedical’s published Clinical studies have demonstrated in the case of prostate and breast cancer 92%+ accuracy in detecting the genetic fingerprints associated with these cancers.

 

A screening test is particularly useful for people in high risk groups either because of lifestyle risks, hereditary risks or those who have had a positive test for gene faults associated with particular cancers such as BRACA 1 & 2.

 

Additionally as CNI Second Opinion™ for men who have elevated PSA (risk of prostate cancer), or women with indeterminate mammogram results, CNI technology can assist in determining whether a patient needs a tissue biopsy.

 

Further our CNI Monitor can monitor patient in remission and/or predict treatment outcomes six to twelve weeks ahead of present methodologies.

An aid to diagnosis from a blood sample rather than invasive biopsy

Highly accurate in detecting the fingerprints for cancer

Non-invasive and without radiation, safe for pregnant and nursing mothers

Scans the whole human genome, detecting most of cancers

Results within 2 weeks

The earlier you can detect cancer the better the outcome in the majority of cases

The Chronix blood test measures CNI and gives real time risk of an individual suffering cancer

WHO:

bauble-blue
If you are in a high risk group such as smokers, or those with a family history of cancer, those who have had cancer in the past and wish to carefully monitor for any early indications of recurrence.

 

bauble-blue
If you have had a recent PSA test that is raised and wish to have a second opinion prior to a biopsy or if you wish to have confirmation of a biopsy result as prostate biopsies have a significant number of false negative results.

 

bauble-blue
For those people who have an increased risk of breast cancer following tests showing gene mutations such as BRCA 1 or 2. It is also a test that can be used to help doctors determine more accurately the presence or otherwise of breast cancer in those who have had inconclusive mammography results.

 

bauble-blue
Upon diagnosis of cancer and prior to and after your treatment starts in order to determine if your treatment is working after a single cycle of treatment.

 

bauble-blue
The Chronix blood tests are perfectly safe for anyone to undertake whether they are receiving treatment, elderly or in fact pregnant. It is a simple blood draw of two tubes of 16ml of blood which goes to our laboratory for whole genome sequencing.

HOW:

You simply contact us on the telephone, or go to our web page advancedcancerdiagnostics.com and fill out the enquiry form and one of our medical team will contact you within 24 hours to take you through what happens next.
Our tests

CNI Screen – CNI Cancer Evaluation Test

The Chronix Biomedical CNI Cancer Evaluation Test is a screening method to detect some cancers before they are noticed by symptoms. When cancer cells die they can shed their content into the blood stream, where this material is then transported in the liquid part of the blood, the so-called blood plasma. In many cancers duplications or deletion of large sections of DNA can be detected in blood, which we use in our test. If the altered DNA concentration present in blood is high enough to detect there is the opportunity to discover a cancer before symptoms occur.

 

Our assay will calculate a measured value based on the 16 ml blood sample you provide. If the measured value is within the limits of what we find in healthy people, there is no evidence in the sample of a cancer at that point in time. If the first result shows a higher value, we will recommend further diagnostic measures to your doctor.

CNI Second Opinion™ Prostate Cancer Evaluation Test

Chronix Biomedical has now made available a laboratory developed test for the detection of risk factors highly associated with prostate cancer. Through the simple process of drawing blood, we can now offer a test that can, with a high degree of accuracy, detect macromolecular mutations of DNA fragments in blood plasma, which are closely associated with prostate cancer.

 

The Chronix Biomedical CNI Second Opinion™ Prostate Cancer Evaluation blood test was designed to be a supplemental test for men with elevated PSA, or those who have had a negative biopsy but wish to seek reassurance.

 

This test will supplement the information you have about test results from PSA tests or imaging enabling you to make a decision based on all the evidence to proceed to a tissue biopsy or test again at a later date.

CNI Monitor – Delta Dot Treatment Outcome Evaluation Test

The Chronix Biomedical Delta Dot Treatment Outcome Evaluation blood test is a vast improvement over the current methods of determing whether a patient is responding to therapy or not. The essential difference is that now for the first time, due to Next Generation Sequencing we can detect cancer mutations of DNA in blood plasma. Advantages of this new technology, are that we can now look at the entirety of the body relating to cancer. Current scanning and tissue biopsy can only look at a specific part of the body.

CNI Second Opinion™ Breast Cancer Evaluation Test

The Chronix Biomedical CNI Second Opinion™ Breast Cancer Evaluation Test is recommended for those people who have an increased risk of breast cancer following tests showing gene mutations such as BRCA 1 or 2. It is also a test that can be used to help doctors determine more accurately the presence or otherwise of breast cancer in those who have had inconclusive mammography results.

Patient Consent

Please note, that Chronix tests are known as „Laboratory developed tests” that doctors use to help make medical decisions. There is a Chance of false positive and false negative results. A patient taking blood sample of our tests must be aware of this statement and sign a Consent Form.

Different-outcome-scenarios

Medical Partners

Dr. Paul Ettlinger

Dr. Paul Ettlinger

BM, DRCOG, MRCGP, DOccMed, a member of the Royal College of General Practioners and holds a Postgraduate Diploma in Obstetrics and Gynaecology and in Occupational Health. Founder of The London General Practice.

Dr. Andrzej Borkowski

Professor Medicine University of Warsaw, Head of Urology 1992 – 2012. His main areas of interest include uro-oncology, reconstructive surgery of the urinary tract and BPH (benign prostatic hyperplasia).

Dr. Andrzej Borkowski

WORIED ABOUT YOUR HEALTH?

Get tested for cancer presence.
Discover the revolutionary CNI test.

CONTACT US

Advanced Cancer Diagnostics

 

bauble-blue
28 Bolton Street London W1J 8BP

 

bauble-blue
Tel: +44 207 629 9933

 

bauble-blue
advancedcancerdiagnostics.com
chronixbiomedical.com
enquiries@advancedcancerdiagnostics.com